Latest Prostate cancer Stories

Effectiveness Of Prostate Cancer Therapy Reduced With Emotional Stress

2013-01-28 12:07:40

Beta-blockers offer some protection Not surprisingly, a cancer diagnosis creates stress. And patients with prostate cancer show higher levels of anxiety compared to other cancer patients. A new study by researchers at Wake Forest Baptist Medical Center indicates that stress is not just an emotional side effect of the diagnosis; it also can reduce the effectiveness of prostate cancer drugs and accelerate the development of prostate cancer. The findings are published in the February...

Stress Feeds Prostate Cancer Cells

2013-01-28 12:00:31

Prostate cancer patients have increased levels of stress and anxiety; however, several recent studies have found that men who take drugs that interfere with the stress hormone adrenaline have a lower incidence of prostate cancer. In this issue of the Journal of Clinical Investigation George Kulik and colleagues at Wake Forest University examined the relationship between stress and cancer progression in a mouse model of prostate cancer. Kulik and colleagues found that mice that had been...

Prostate Cancer Core Facts for 2013

2013-01-25 12:25:07

NEW YORK, Jan. 25, 2013 /PRNewswire/ -- The impact of prostate cancer on American men will be significant in 2013, according to the "Cancer Facts & Figures 2013" report by the American Cancer Society (ACS) (http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-036845.pdf). The ACS projects that nearly 240,000 new cases of prostate cancer will account for 28 percent of all male cancers this year. Despite the disease's prevalence, prostate...

Varian Medical Systems Receives FDA 510(k) Clearance for Vitesse(TM) Brachytherapy Treatment Planning Software

2013-01-24 08:31:43

PALO ALTO, Calif., Jan. 24, 2013 /PRNewswire/ -- Varian Medical Systems (NYSE: VAR) has received an FDA 510(k) clearance for the latest version of its Vitesse(TM) real time planning for HDR brachytherapy which is used to plan and perform high-dose-rate (HDR), ultrasound-guided brachytherapy treatments for prostate cancer. "This version of Vitesse reduces the number and complexity of steps involved in planning and completing a treatment. It eliminates the need for a data transfer...

Genomic Health Announces New Evidence Further Demonstrating Clinical Utility and Cost-Effectiveness of Oncotype DX in Colon Cancer

2013-01-23 08:28:57

REDWOOD CITY, Calif., Jan. 23, 2013 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results from three studies of the Oncotype DX(®) Colon Cancer test at the 2013 Gastrointestinal (GI) Cancers Symposium, including new data demonstrating that Recurrence Score(®) (RS) results changed treatment recommendations in 45 percent of the enrolled stage II colon cancer patients. Presentations also include positive findings from a second health economics analysis...

Quest PharmaTech Enrolls 40th Patient in its Phase II Oregovomab Front-Line Chemo-Immunotherapy Clinical Trial for Ovarian Cancer in Italy and the U.S.

2013-01-22 12:27:30

TSX Venture: QPT EDMONTON, Jan. 22, 2013 /PRNewswire/ - Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company developing and commercializing products for the treatment of cancer, announces that it has achieved 50% accrual having enrolled the 40(th) patient in its ongoing 80 patient Phase II Oregovomab front-line chemo-immunotherapy clinical trial in Italy and the U.S. The objective of this study is to confirm that optimally dosed oregovomab in...

Prostate Cancer Robotics: "Radiosurgery" Is Not Real Surgery

2013-01-22 08:31:22

NEW YORK, Jan. 22, 2013 /PRNewswire/ -- Not all robots are created equal, particularly when it comes to prostate cancer, says world-renowned prostate cancer surgeon, Dr. David Samadi. Specializing in minimally invasive da Vinci robotic prostatectomy surgery, Dr. Samadi is not only Vice Chairman, Department of Urology at The Mount Sinai Medical Center; he is also Chief of Robotics and Minimally Invasive Surgery. (Photo: http://photos.prnewswire.com/prnh/20130122/NY45644 ) Robots...

Low T Center Opens 12th Texas Location Near Houston, Hits 20 Mark Nationally

2013-01-21 12:23:24

HOUSTON, Jan. 21, 2013 /PRNewswire/ -- Low T Center, Texas' number one authority on the treatment of low testosterone in men, is once again expanding its presence in the state with the opening of its 12th Texas location today near Houston. The new Low T Center in Friendswood, south of Houston, is the fifth location in the Houston area. The other Houston Low T Centers are at The Woodlands, Katy, the Galleria area and in Vintage Park. (Logo:...

MetaStat to Present at Noble Financial Capital Markets' Ninth Annual Equity Conference on January 22, 2013

2013-01-18 08:23:32

MONTCLAIR, N.J., Jan. 18, 2013 /PRNewswire/ -- MetaStat, Inc. (OTCBB: MTST), ("MetaStat" or the "Company"), a life science company focused on understanding and treating systemic metastasis, today announced that the Company will be presenting at the NINE 2013 - Noble Financial Capital Markets' Ninth Annual Equity Conference held at the Hard Rock Hotel & Casino, Hollywood, Florida, on Tuesday, January 22, 2013 at 4:30 p.m. Eastern Time. Dr. Oscar Bronsther, Chief Executive Officer...

Biscayne Pharmaceuticals Closes $1.5 Million Financing To Advance Recent Discoveries Of Pioneering Endocrine Drug Researcher

2013-01-18 08:23:29

MIAMI, Jan. 18, 2013 /PRNewswire/ -- Biscayne Pharmaceuticals, Inc. today announced that it has closed a $1.5 million financing. The new company is developing novel growth hormone-releasing hormone (GHRH) drugs based on recent discoveries by the company's scientific advisor, Dr. Andrew V. Schally, a world-renowned drug researcher and Nobel laureate who pioneered the field of hypothalamic peptide drugs. Biscayne also announced that it has exclusively licensed intellectual...